Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients

Y Miyazaki, R A DeFronzo
Diabetes, Obesity & Metabolism 2008, 10 (12): 1204-11

OBJECTIVE: We examined the effects of rosiglitazone treatment on profiles of adipocytokines levels, postprandial insulin and glucose excursion, lipids levels, comparing with those of pioglitazone treatment in patients with type 2 diabetes mellitus (T2DM).

METHODS: Changes in body weight, haemoglobin A(1c )(HbA(1c)), glucose/insulin/C-peptide/free fatty acid (FFA) during 75 g oral glucose tolerance test (OGTT), HDL-/LDL-cholesterol, triglyceride (TG) and adipocytokines [tumour necrosis factor (TNF)-alpha, leptin and adiponectin] were measured in T2DM patients treated with rosiglitazone, 8 mg/day (n = 35), or pioglitazone, 45 mg/day (n = 21), for 3 months.

RESULTS: After rosiglitazone or pioglitazone treatment, HbA(1c )(8.6-7.2 vs. 8.3-6.9%, rosiglitazone vs. pioglitazone), fasting plasma glucose (190-144 vs. 178-140 mg/dl), fasting FFA (729-595 vs. 641-526 microEq/l), mean plasma glucose-OGTT (292-229 vs. 285-233 mg/dl) and mean FFA-OGTT (580-430 vs. 488-377 microEq/l) decreased similarly and all were statistically significant (p < 0.01). The insulinogenic index (DeltaI(0-120)/DeltaG(0-120)) (0.19-0.30 vs. 0.17-0.26) and Matsuda index of insulin sensitivity (2.0-3.1 and 2.7-4.3) increased (p < 0.01) similarly, despite increase in body weight (85-88 vs. 81-84 kg). TNF-alpha (3.8-3.4 vs. 5.2-4.5 pg/ml) decreased (p < 0.05) and adiponectin (6.3-17.8 vs. 7.1-16.4 microg/ml) increased (p < 0.01), while leptin did not change following either treatment. After rosiglitazone treatment, plasma HDL-cholesterol (34-38 mg/dl) and LDL-cholesterol (103-120 mg/dl) increased (p < 0.01), while TGs (177-167 mg/dl) did not change significantly. After pioglitazone treatment, plasma HDL-cholesterol (34-37 mg/dl) increased (p < 0.05), while LDL-cholesterol (104-105 mg/dl) did not change and TGs (153-106 mg/dl) decreased (p < 0.01).

CONCLUSIONS: Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels. However, pioglitazone has a more beneficial effect on the plasma lipid profile than rosiglitazone.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"